Clinical Trial News and Research

RSS

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Trophos today announces that top-line results from a pivotal clinical trial of its lead product candidate olesoxime in spinal muscular atrophy (SMA) show a beneficial effect on the maintenance of motor function in SMA patients. If approved, olesoxime could be the first treatment specifically developed for SMA patients.

10 Mar 2014

First Edition: March 10, 2014

Today's headlines include reports about how the Virginia Assembly's impasse on Medicaid expansion is playing out.

10 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Mainstay Medical today announced that it has secured approval from Ethics Committees in Australia to start a clinical trial of ReActiv8, its innovative implantable neurostimulation device for the treatment of people with Chronic Low Back Pain (CLBP). Recruitment of subjects for the trial has commenced at three clinical sites in Australia.

10 Mar 2014

Biomarkers for bone resorption predict outcomes for men with prostate cancer

Biomarkers for bone formation and resorption predict outcomes for men with castration-resistant prostate cancer, a team of researchers from UC Davis and their collaborators have found.

10 Mar 2014

Scientists develop new nasal filter that helps people with nasal symptoms from seasonal hay fever

A small filter the size of a contact lens could possibly make life easier for some of the estimated 500 million people worldwide who suffer from itching, sneezing and a runny nose as soon as the pollen season starts.

10 Mar 2014

Inherited Alzheimer's neuronal damage begins 10 to 20 years before symptoms appear

In a paper published in the prestigious journal Science Translational Medicine, Professor Colin Masters from the Florey Institute of Neuroscience and Mental Health and University of Melbourne - and colleagues in the UK and US - have found rapid neuronal damage begins 10 to 20 years before symptoms appear.

10 Mar 2014

Edison Pharmaceuticals initiates Phase 2B/3 study of EPI-743 in children with Leigh syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled, "A Phase 2B/3 Open-label Study of EPI-743 in Children with Leigh Syndrome" to be conducted in conjunction with Dainippon Sumitomo Pharma Co, Ltd.

10 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care.

9 Mar 2014

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Researchers at the University of California, San Diego School of Medicine have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against the most aggressive form of primary brain cancer, glioblastoma. The finding was published in this week's online edition of Oncotarget.

8 Mar 2014

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Three longtime allies have joined forces to create the new Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

7 Mar 2014

National clinical trial to test new avenue for tinnitus treatment

UT Southwestern Medical Center will take part in a national clinical trial to test a device that could provide relief for people suffering from tinnitus, a persistent buzzing or ringing sound in the ears. The device uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus.

7 Mar 2014

Columbia Laboratories repurchases Actavis' block of shares at advantageous price

Columbia Laboratories, Inc. announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014.

7 Mar 2014

New method of protecting women from transmission of HIV is safe

Findings of an early phase clinical trial at the University of Alabama at Birmingham suggest that a possible new method of protecting women from the transmission of HIV is safe.

7 Mar 2014

Cataract surgery followed by use of contact lenses may be better solution for infants

For adults and children who undergo cataract surgery, implantation of an artificial lens is the standard of care. But a clinical trial suggests that for most infants, surgery followed by the use of contact lenses for several years—and an eventual lens implant—may be the better solution.

7 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Tetraphase Pharmaceuticals, Inc. today reported financial results for the quarter and full year ended December 31, 2013.

6 Mar 2014

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Clinical Trial News and Research

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

First Edition: March 10, 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Mainstay Medical initiates clinical trial to investigate ReActiv8 as treatment for adults with CLBP

Biomarkers for bone resorption predict outcomes for men with prostate cancer

Scientists develop new nasal filter that helps people with nasal symptoms from seasonal hay fever

Inherited Alzheimer's neuronal damage begins 10 to 20 years before symptoms appear

Edison Pharmaceuticals initiates Phase 2B/3 study of EPI-743 in children with Leigh syndrome

Erlotinib has promising potential to improve treatment for cervical cancer

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

National clinical trial to test new avenue for tinnitus treatment

Columbia Laboratories repurchases Actavis' block of shares at advantageous price

New method of protecting women from transmission of HIV is safe

Cataract surgery followed by use of contact lenses may be better solution for infants

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery